©The Author(s) 2025.
World J Nephrol. Sep 25, 2025; 14(3): 102667
Published online Sep 25, 2025. doi: 10.5527/wjn.v14.i3.102667
Published online Sep 25, 2025. doi: 10.5527/wjn.v14.i3.102667
Table 1 Pharmacokinetic/pharmacodynamic profiles and continuous kidney replacement therapy dosing recommendations for selected antibiotics
| Antibiotics | PK/PD index | PK profile | Renal clearance (%) | Suggested CKRT dosing |
| β-lactam (prolonged infusion strategies should be used with drug/brand specific stability data) | ||||
| Aztreonam | %T > MIC | MW: 435[100]; PB: 56%; Vd: 0.15-0.18 L/kg | 60-70 | 2 g every 8 hours |
| Cefepime | %T > MIC | MW: 481; PB: 20%; Vd: 0.3 L/kg | 85 | 2 g every 8-12 hours |
| Ceftazidime | %T > MIC | MW: 547; PB < 10%; Vd: 0.28-0.4 L/kg | 60-85 | 2 g every 8 hours |
| Imipenem/cilastatin | %T > MIC | MW: 317/380; PB: 20/40%; Vd: 0.22-0.24 L/kg | 20-70/60 | 500 mg every 6-8 hours |
| Meropenem | %T > MIC | MW: 383; PB: 2%; Vd: 0.35 L/kg | 70 | 1-2 g every 8 hours |
| Piperacillin-tazobactam | %T > MIC | MW: 518/300; PB: 26-33/31%-32%; Vd: 0.24/0.40 L/kg | 75-90/65 | 4.5 g every 8 hours |
| Novel agents BL/BLI (prolonged infusion strategies should be used with drug/brand specific stability data) | ||||
| Cefiderocol | %T > MIC | MW: 752; PB: 40%-60%; Vd: 18 L | 90 | 1.5 g every 12 hours to 2 g every 8 hours[17] |
| Ceftazidime-avibactam | %T > MIC | MW: 637/265; PB: < 10%; Vd: 14-17 L | 80-90 | 1.25 g every 8 hours |
| Ceftolozane-tazobactam | %T > MIC | MW: 765/322; PB: 16%-21%; Vd: 13-18 L | 66 | 1.5 g every 8 hours, 1.5-3 g every 8 hours[17] |
| Imipenem-relebactam | %T > MIC | MW: 317/366; PB: 20%; Vd: 24 L | 63 | 1.25 g single dose, followed by 0.75 g every 6 hours |
| Meropenem-vaborbactam | %T > MIC | MW: 437/297; PB: 2%; Vd: 19 L | 40-60 | 2 g every 8 hours |
| Aminoglycosides (aminoglycosides dosing recommendations are in the context of systemic gram-negative infections) | ||||
| Amikacin | Cmax/MIC | MW: 586; PB: 0%-11%; Vd: 0.22-0.5 L/kg | 95 | 15-25 mg/kg every 48 hours with TDM; 25 mg/kg every 48 hours combined with TDM[50] |
| Gentamicin | Cmax/MIC | MW: 478; PB: < 30%; Vd: 0.36 L/kg | 95 | 3-5 mg/kg every 24-48 hours with TDM; 7 mg/kg every 24 hours with high dose of 40 mL/kg/hour CKRT dose[53] |
| Glycopeptides | ||||
| Vancomycin | AUC24/MIC | MW: 1448; PB: 55%; Vd: 0.47-1.1 L/kg | 90-100 | Load 20-25 mg/kg followed by 7.5-10 mg/kg every 12 hours with AUC monitoring[58] |
| Fluoroquinolones | ||||
| Ciprofloxacin | AUC24/MIC | MW: 331; PB: 20-40%; Vd: 2.5 L/kg | 50-70 | 400 mg IV every 8-12 hours |
| Levofloxacin | AUC24/MIC | MW: 361; PB: 24-38; Vd: 1.1-1.5 L/kg | 67-87 | 750 mg IV once followed by 750 mg IV every 24 hours with effluent flow rates > 20 mL/kg/hour[11] |
| Lipopeptides | ||||
| Daptomycin | AUC24/MIC | MW: 1620; PB: 90%-93%; Vd: 0.1-0.13 L/kg | 78 | 6 mg/kg every 24 hours; 8-10 mg/kg every 24 hours[49,61] |
- Citation: Tee C, Ngai M, See KC. Antimicrobial dosing considerations in critically ill patients with acute kidney injury: A review. World J Nephrol 2025; 14(3): 102667
- URL: https://www.wjgnet.com/2220-6124/full/v14/i3/102667.htm
- DOI: https://dx.doi.org/10.5527/wjn.v14.i3.102667